Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoStart with Pro — $79/mo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Acquisition/DispositionItem 2.01 · 8-KLOW RiskNeutral

Voyager Therapeutics, Inc.

Filed: Mar 9, 2026CAMBRIDGE, MACIK: 0001640266
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Voyager Therapeutics announced its fourth quarter and full year 2025 financial results on March 9, 2026, providing stakeholders with key performance metrics and corporate updates that are essential for evaluating the company's operational status and strategic direction.

Key Takeaways

Company reported full year 2025 financial results including fourth quarter performance metrics

Corporate updates were provided alongside financial announcement to inform stakeholder decision-making

2 more takeaways

Related Filings (1)

1 more filing from Voyager Therapeutics, Inc. in the last 90 days

Filing Overview

Form Type8-K
Filing DateMar 9, 2026
Item2.01
CategoryAcquisition/Disposition
CIK0001640266
Accession #0001640266
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
earnings

What This Means

The company completed a major acquisition or sold off a significant asset. This reshapes the company's portfolio and strategic direction.
View Full Filing on SEC.govBrowse More Filings